Conference Call 3 rd Quarter 2007 Results

Disclaimer This document contains “forward-looking statements”. Forward-looking statements may be identified by words such as “expects”, “plans”, “believes”, “seeks”, “estimates” or words with similar meaning. The statements contained in this presentation about the Company's forward-looking statements, including business prospects, operating and financial projections and potential growth are merely forecasts based on management’s expectations in relation to its future performance. Such estimates are highly dependent on market behavior, on Brazil’s economic performance and on industry and international market conditions. As such, they are subject to change. 1

Executive Summary  In November 2007, DASA will be listed in Bovespa for 3 years;  In this short period of time, DASA almost doubled its size through brand segmentation, introduction of imaging services and geographic expansion to new markets.  Despite the strong growth, gross margin did not oscillate significantly. Gross Revenues Evolution (R$ Millions) Gross Margin Evolution (%) Q043Q %

M % 23.4% 21.4% Jul 07 vs Jul 06Ago 07 vs Ago 06Set 07 vs Set 06 Executive Summary – cont.  Similarly important is DASA´s entrance in new dynamic market segments which still have a host of opportunities of consolidation.  During the quarter, besides the acquisition of CientíficaLab and Med Imagem, we opened 11 new patient service centers (2 of which were mega). The acceleration of acquisitions and organic growth has already influenced the 3Q07, specially as of September. Monthly Revenue Growth vs 2006 Lab-to-lab Gross Revenue (R$ Million)Gross Revenue per Segment (3Q07) 3 * DASA´s segment of operation during the IPO (e) Projected (B) Budget 20069M074T07 (e)2008 B Mega4254 Standard Total (e) (B) Budget 20069M074Q07 (e)2008 B Mega4254 Standard Total

Third Quarter 2007 – Highlights 4  Opening of 11 PSCs, 2 of which were “megas”, adding 24 new patient service centers in 2007 and 36 in the last 12 months;  Entry in the public sector, through the acquisition of CientíficaLab (Jul/07);  Acquisition of Med Imagem (Aug/07) with operations in Rio de Janeiro;  Strong requisition volume growth: 21.6% in outpatient and inpatient segment and 34.6% in the lab- to-lab segment;  Adjusted EBITDA margin of 23.8%, despite acceleration of the expansion strategy.

Gross Revenue Growth (R$ Million) Gross Revenue by Service Line (R$ Million) Operating Revenue by Service Line  Growth of 29.8% in gross revenue, which reached R$ million in the quarter, the highest quarterly growth achieved since the IPO in November of 2004;  This result is due to revenues from organic expansion and acquisitions in the outpatient and inpatient segments (+17.7%); growth of lab-to-lab operations (+19.5%); and the entry in the public service sector through CientíficaLab;  Same-unit revenues grew by 2.2% in the 3Q07;  The entrance in the public healthcare sector (SUS) helped dilute the share of traditional payers in DASA’s revenue Q063Q07 CAGR = 22.3% 29.8% Q063Q07 Outpatient & InpatientReferencePublic Sector % 29.8% 19.5% 91.5% 8.5% 82.9% 7.9% 9.2%

Q064Q061Q072Q073Q07 RequisitionsAverage revenue per requisition 6 Operating Revenue – Outpatient & Inpatient  In the last 12 months, 4 companies were acquired in this segment: VitaLâmina, Atalaia, Exame and Med Imagem;  Growth in imaging services is still significant (+15.2%) despite a dilution of 0.8 p.p. due to the nature of the acquisitions done in the last twelve months. Excluding this effect, the share of imaging services moved up by 1.1 p.p.;  The growth in clinical analysis revenue, up by 19.2% over the same period of 2006, was fueled by 2006 and 2007 acquisitions;  As observed, the average revenue per requisition is stable. The decline comparing to the 3Q06 (-3.2%) was solely a result of the change in the revenue mix, as the average clinical analysis prices remained flat and the average imaging prices grew by 4.3%. Average Revenue per Requisition (R$) and Requisition Volume (Million) Revenue by Service line (RS Million) Q06 3Q07 Clinical Analysis Imaging Services % 37.4% 63.4% 36.6% % 15.2% 19.2%

Q062Q063Q064Q061Q072Q073Q07 Average revenue/laboratory (in R$ million ) Average revenue/requisition(in R$) # Requisitions/laboratory 7 Operating Revenue – Lab-to-lab  Lab-to-lab revenue grew by 19.5% as a result of an upturn in the number of laboratories served (from 2,119 in 3Q06 to 2,427 in 3Q07) and an increase in the average revenue per laboratory;  The average revenue per laboratory moved up by 4.3% y-o-y due to a growth of 17.5% in the number of requisitions processed by laboratory. This result corroborates our strategy of expansion of Alvaro’s services to laboratories which are already clients, through the offering of less complex tests, which present lower average prices. Revenue – Support activities (R$ million) Performance analysis - Alvaro Q063Q07 CAGR = 49.7% 19.5%

CientíficaLab – Revenue (R$ million) 8.0* Q063Q % 8 Operating Revenue – Public Sector  The expansion of CientificaLab’s services, currently in São Paulo, Minas Gerais and Rio de Janeiro, foresees an increase in the volume of tests per existing contract and the opening of new contracts for other states and municipalities;  CientíficaLab, a leading private service provider to the public sector, served 36 clients when acquired and now has 40 clients, classified between medium-sized (up to 150 thousand tests processed per month) and large-sized (more than 150 thousand per month) clients;  In this quarter, CientíficaLab’s revenue represented 9.2% of total gross revenue totaling R$ 23.4 million and up by a substantial 193.4% over the 3Q06. CientíficaLab – Client Classification MédioGrande Porte Final do trimestre Momento da aquisição Total Medium Size Large Size End of the Quarter Moment of acquisition Total *Non-Audited

Gross Profit and Costs  The gross margin fell by 4.6 p.p. in relation to 3Q06 due to fixed costs generated by the opening of new PSCs, the larger share of business-to-business operations (Alvaro and CientíficaLab) and new hospitals;  The rise in personnel costs and general expenses are a consequence of the opening of 36 new PSCs in the last 12 months, which are still in ramp-up, and of the 5 new acquisitions in the same period, as we have not yet captured all the possible synergies, especially in central labs;  The upturn in material costs is due to the growth in business-to-business activities, where such costs are higher in relation to net revenue. “Cash-Cogs” Evolution (3Q06 vs. 3Q07) “Cogs” – 3Q07 (% of Total Cash Cogs) % 1.0% (0.1%) 1.8% 1.9% 56.4% Cash Cogs 3Q06 Personnel Costs Materials Services and Utilities General Expenses Cash Cogs 3Q % 34.5% 12.7% 23.6% PersonnelMaterial Services and UtilitiesGeneral costs 7.1% 51.9% 34.5% 6.5% B2C*B2B *B2C = Outpatient & Inpatient

Operating Expenses  3Q07 operating expenses reached R$65.0 million, with lower General and Administrative expenses and higher goodwill amortization expenses mainly related to the acquisitions and financial expenses;  The dilution of 0.4 p.p. in the expenses that affect EBITDA is a result of the dilution of expenses in the parent company (2.0 p.p.), partially offset by the increase in subsidiary expenses (1.7 p.p.), due to the five companies acquired since October 2006;  These subsidiary expenses tend to be diluted as they are integrated to DASA. 10

EBITDA and adjusted EBITDA EBITDA and adjusted EBITDA (R$ Million)  Adjusted EBITDA increased by 11.5% and EBITDA grew 9.2% in 3Q07;  Despite the acquisition of five new operations during the last 12 months and recently opened PSCs still maturing, the adjusted EBITDA margin for the 3Q07 reached 23.8%, representing an upturn comparing to 2Q Q063Q07 Non-recurring expenses EBITDA Adjusted EBITDA CAGR = 22.0% 11.5% Q061Q072Q073Q07 EBITDA margin22.5%20.5%26.5%23.0%20.9%22.3% Adjusted EBITDA margin25.7%25.0%27.7%24.7%22.6%23.8%

 CAPEX totaled R$ 56.9 million in the quarter;  In the parent company, investments were primarily focused on (i) the purchase of imaging equipment and PSC construction – specially to the 7 mega PSC´s forecasted to the second semester of 2007, (ii) the construction of the new call center and (iii) images digitalizing equipments;  In the subsidiaries, the most relevant investments were made in the new Central Lab in São José dos Pinhais (PR) and testing equipment for CientíficaLab’s hospitals. CAPEX CAPEX (R$ million) CAPEX Breakdown (3Q07) Q063Q07 Parent CompanySubsidiaries

 The acquisitions of CientíficaLab and Med Imagem, along with the quarter’s investments in organic expansion, consumed cash flow and required additional funds;  The Company’s net debt reached to R$ million. Cash Flow and Indebtedness Cash Flow Analysis (R$ million) Cash Flow 3Q07 EBITDA 52.1 Taxes (0.7) Net Financial (7.0) Working Capital and Others (25.8) 18.6 Generated Cash Flow Cash and Cash Equivalents65.8 Short-term Debt (77.5) Long-term Debt (*) (303.3) Net Debt (339.5) (+) Escrow Deposits47.9 (*) Includes Escrow 13 (132.0) (56.9) (133.1) 18.6 (303.3) 2Q07 Net Debt Cash Flow Generated CAPEXAcquisition3Q07 Net Debt Net Debt Breakdown (R$ million)

 The revenue growth accelerated in 3Q07 and we believe the scenario will remain positive;  The acquisitions already done, the opened PSCs, investments in image digitalizing and equipments acquisitions, besides the resources invested in IT, will contribute to the future growth;  For 2008, we will proactively pursue acquisitions that allow us not only enter in new markets, but also reinforce our position in regions where DASA already operates. Conclusions Gross Revenue per Payer (12M06) 14 Gross Revenue per Payer (3Q07)

DASA – Investor Relations Av. Juruá, 434 Barueri – Alphaville – São Paulo Phone: Website: